CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

This milestone builds upon phase one of the virtual clinic ... we can now facilitate clinical research on the HALO™ device while preparing for broader patient adoption. By creating a seamless ...

The first phase of construction is beginning on a new $2.19 billion health care, training and research facility for UNMC and ...

core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose ...

From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster ...

Nexalin Technology (NXL), announced the completion and launch of phases one through ... remote monitoring, and clinical oversight of its HALO headset in both research and patient treatment settings.

The Phase 2 clinical trial of MB-105 (NCT06534060 ... support from the Cancer Prevention & Research Institute of Texas (CPRIT), and the NIH SBIR program. Learn more at www.march.bio. This press ...

Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian ...

CERo Therapeutics Holdings, Inc. has announced that the Sarah Cannon Research Institute at the Colorado Blood Cancer Institute will be a key clinical trial site for its Phase 1 trial of CER-1236 ...